US-based radiation oncology firm Accuray has received the US Food and Drug Administration (FDA) 510(k) clearance for its Radixact treatment delivery platform.
The next-generation hardware and software solutions constitute the new Radixact system and promote faster and more efficient delivery of precise treatment for a wider range of cancers.
University of Wisconsin School of Medicine and Public Health clinical associate professor Jennifer Smilowitz said: "The Radixact System builds upon the unique strengths of the TomoTherapy platform.
"Expanded delivery capabilities enable treatment with image-guided, intensity-modulated radiation therapy (IG-IMRT, an extremely accurate form of radiation therapy) to an expanded range of patients.
"New database features make the ring gantry-based system even easier to operate and integrate within a radiation oncology department."
The Radixact system is incorporated with a powerful linear accelerator, MVCT imaging and helical treatment delivery which allow clinicians to apply highly conformal and homogenous dose distributions to any target volume while leaving the normal healthy tissue unscathed.
The clinicians can tailor the delivery of their treatment in accordance to changes in tumour size, shape and location within the patient by virtue of the smart, automated workflows and midcourse decision-making tools, which feature in the new Accuray precision treatment planning system.
The Radixact System is expected to be commercially available at the end of next year.
Image: Radixact Treatment Delivery System. Photo: courtesy of PRNewsFoto / Accuray Incorporated.